Daily Briefing
Friday, February 13, 2026
The Vibe
Payers are betting big on AI to cut costs while researchers keep churning out mortality prediction models that may never see clinical use. Anterior's $40M funding round signals serious money flowing into AI-powered prior authorization, where the real savings live [1]. Meanwhile, academic labs produce another batch of deep learning models for everything from heart failure to kidney injury—impressive on paper, questionable in practice.
Research
•ECG-based deep learning predicts short-term mortality in heart failure patients, though specifics on performance metrics remain buried in methodology [2]
•RAG-enhanced large language models now tackle drug-induced liver injury using Livertox data, potentially streamlining hepatotoxicity assessment [3]
•Machine learning identifies predictors for chronic post-surgical pain after thoracoscopic surgery, targeting a notoriously difficult clinical problem [4]
•NICU mortality risk models for acute kidney injury patients show promise, addressing a vulnerable population where every prediction counts [5]
Clinical Practice & Ops
•Anterior raises $40M to expand AI-powered prior authorization platform, targeting the $300B annual waste in healthcare administrative costs [1]
•Bristol Myers partners with Evinova's AI-native clinical development platform globally, aiming to slash trial timelines and costs [6]
•Mayo Clinic's COO reveals 100 petabytes of EHR data with 28 petabytes de-identified using proprietary methods, questioning standard de-identification approaches [7]
Industry & Products
•Hinge Health projects $732M revenue by 2026, driven by AI investments and strong growth in digital therapeutics [8]
•GE HealthCare launches remote maintenance technology for bedside ECG stations, addressing the growing burden of connected device management [9]
One to Watch
Monitor how Anterior's prior auth AI performs in real-world cost reduction—if it delivers on promises, expect a flood of payer AI investments. The gap between academic prediction models and clinical deployment continues to widen.